Clinical Practice Guidelines: management of hepatitis C virus infection, J Hepatol, vol.60, issue.12, pp.392-420, 2014. ,
No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B, Hepatology, vol.51, issue.2, pp.434-476, 2014. ,
DOI : 10.1002/hep.26686
Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B, Hepatology, vol.2, issue.Suppl. 1, pp.422-452, 2010. ,
DOI : 10.1002/hep.23327
Magnitude of Virologic Blips Is Associated With a Higher Risk for Virologic Rebound in HIV-Infected Individuals: A Recurrent Events Analysis, Journal of Infectious Diseases, vol.205, issue.8, pp.1230-1238, 2012. ,
DOI : 10.1093/infdis/jis104
Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis B Improving the measurement of self-reported medication nonadherence: response to authors, Hepatology Clin Infect Dis World J Gastroenterol J Clin Epidemiol, vol.605613864, pp.497-507, 2007. ,
Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of na??ve patients with a partial virological response, Hepatology, vol.49, issue.5 Suppl., pp.443-51, 2011. ,
DOI : 10.1002/hep.24406
Effects of Tenofovir Disoproxil Fumarate in Hepatitis B e Antigen-Positive Patients With Normal Levels of Alanine Aminotransferase and High Levels of Hepatitis B Virus DNA, Gastroenterology, vol.146, issue.5, pp.1240-1248, 2014. ,
DOI : 10.1053/j.gastro.2014.01.044
Efficacy of Entecavir With or Without Tenofovir Disoproxil Fumarate for Nucleos(t)ide-Na??ve Patients With Chronic Hepatitis B, Gastroenterology, vol.143, issue.3, pp.619-647, 2012. ,
DOI : 10.1053/j.gastro.2012.05.037
Causes and Consequences of Incomplete HIV RNA Suppression in Clinical Trials, HIV Clinical Trials, vol.200, issue.292, pp.289-98, 2009. ,
DOI : 10.1097/01.aids.0000131332.30548.92
Antiviral effect of entecavir in chronic hepatitis B: Influence of prior exposure to nucleos(t)ide analogues, Journal of Hepatology, vol.52, issue.4, pp.493-500, 2014. ,
DOI : 10.1016/j.jhep.2010.01.012
No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus, Hepatology, vol.51, issue.3, pp.763-73, 2011. ,
DOI : 10.1002/hep.24078
Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B, Journal of Hepatology, vol.54, issue.1, pp.12-20, 2011. ,
DOI : 10.1016/j.jhep.2010.06.016
Adherence to nucleos(t)ide analogues for chronic hepatitis B in clinical practice and correlation with virological breakthroughs, Journal of Viral Hepatitis, vol.21, issue.3, pp.205-217, 2012. ,
DOI : 10.1111/j.1365-2893.2011.01494.x
The role of adherence in virological suppression in patients receiving anti-HBV analogues, Antiviral Therapy, vol.17, issue.2, pp.395-400, 2012. ,
DOI : 10.3851/IMP1944
Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough?, Journal of Hepatology, vol.55, issue.6, pp.1468-1477, 2011. ,
DOI : 10.1016/j.jhep.2011.04.006
Altered Functions of Plasmacytoid Dendritic Cells and Reduced Cytolytic Activity of Natural Killer Cells in Patients With Chronic HBV Infection, Gastroenterology, vol.143, issue.6, pp.1586-1596, 2012. ,
DOI : 10.1053/j.gastro.2012.08.046
Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load, Gastroenterology, vol.130, issue.3, pp.678-86, 2006. ,
DOI : 10.1053/j.gastro.2005.11.016
Can transient elastography be used for the management of chronic hepatitis B patients?, Liver International, vol.53, issue.4, pp.528-558, 2012. ,
DOI : 10.1111/j.1478-3231.2012.02768.x
Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study, The Lancet, vol.381, issue.9865, pp.468-75, 2013. ,
DOI : 10.1016/S0140-6736(12)61425-1
Prevalence of hepatitis B and hepatitis C virus infections in France in 2004: Social factors are important predictors after adjusting for known risk factors, Journal of Medical Virology, vol.15, issue.4, pp.546-55, 2010. ,
DOI : 10.1002/jmv.21734
Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load, Gastroenterology, vol.130, issue.3, pp.678-686, 2006. ,
DOI : 10.1053/j.gastro.2005.11.016
Risk of Hepatocellular Carcinoma across a Biological Gradient of Serum Hepatitis B Virus DNA Level, JAMA, vol.295, issue.1, pp.65-73, 2006. ,
Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: A systematic review, Journal of Hepatology, vol.57, issue.1, pp.196-202, 2012. ,
DOI : 10.1016/j.jhep.2011.11.030
Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B, Journal of Viral Hepatitis, vol.13, issue.Suppl. 1, pp.36-44, 2009. ,
DOI : 10.1111/j.1365-2893.2008.01037.x
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial, The Lancet, vol.365, issue.9454, pp.123-129, 2005. ,
DOI : 10.1016/S0140-6736(05)17701-0
A One-Year Trial of Lamivudine for Chronic Hepatitis B, New England Journal of Medicine, vol.339, issue.2, pp.61-68, 1998. ,
DOI : 10.1056/NEJM199807093390201
A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B, New England Journal of Medicine, vol.354, issue.10, pp.1001-1010, 2006. ,
DOI : 10.1056/NEJMoa051285
Telbivudine versus lamivudine in patients with chronic hepatitis B Adefovir dipivoxil for the treatment of hepatitis B antigen-positive chronic hepatitis B, N Engl J Med N Engl J Med, vol.35717348, pp.2576-2588808, 2003. ,
Tenofovir Disoproxil Fumarate versus Adefovir Dipivoxil for Chronic Hepatitis B, New England Journal of Medicine, vol.359, issue.23, pp.2442-2455, 2008. ,
DOI : 10.1056/NEJMoa0802878
Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis BB, Hepatology, vol.27, issue.3, pp.889-896, 1999. ,
DOI : 10.1002/hep.510290321
Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B, New England Journal of Medicine, vol.351, issue.12, pp.1206-1217, 2004. ,
DOI : 10.1056/NEJMoa040431
Entecavir versus Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B, New England Journal of Medicine, vol.354, issue.10, pp.1011-1020, 2006. ,
DOI : 10.1056/NEJMoa051287
Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: Analysis and review of the literature, Hepatology, vol.180, issue.6, pp.1309-1328, 2003. ,
DOI : 10.1053/jhep.2003.50208
Efficacy of entecavir in treatment-na??ve patients with hepatitis B virus-related decompensated cirrhosis, Journal of Hepatology, vol.52, issue.2, pp.176-182, 2010. ,
DOI : 10.1016/j.jhep.2009.11.007
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease, Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease, pp.62-72, 2011. ,
DOI : 10.1002/hep.23952
Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review, Journal of Hepatology, vol.53, issue.2, pp.348-356, 2010. ,
DOI : 10.1016/j.jhep.2010.02.035
Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B, Journal of Hepatology, vol.54, issue.1, pp.12-18, 2010. ,
DOI : 10.1016/j.jhep.2010.06.016
Does adherence to hepatitis B antiviral treatment correlate with virological response and risk of breakthrough?, Journal of Hepatology, vol.55, issue.6, pp.1467-1472, 2011. ,
DOI : 10.1016/j.jhep.2011.04.006
Robin DiMatteob Improving the measurement of selfreported medication nonadherence, J Clin Epidemiol, vol.64, issue.3, pp.255-263, 2011. ,